Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3102 cardiovascular outcomes study in type 2 diabetes
NL-OMON40095Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing MK-3102 once weekly with Placebo once weekly (2 arms). Primary endpoint: Safety and tolerability of MK-3102 25 mg once weekly. Started Sep 2013; status: active, not recruiting.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON40095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40095.